Kanjinti Injection, Powder, Lyophilized, For Solution
Product Images NDC 55513-141

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Kanjinti (NDC 55513-141). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1studies 1 And 2: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 01)

Figure 1studies 1 And 2: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 01)
FDA Label Image

Figure 2study 3: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 02)

Figure 2study 3: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 02)
This appears to be a chart displaying cumulative incidence rates, with observations at various time intervals after randomization. The chart also includes the number at risk for each interval, as well as data regarding the drug Trastuzuma for a one-year time period. Some of the numbers are unreadable, making it difficult to fully interpret the information.*
FDA Label Image

Figure 3study 4: Cumulative Incidence Of Time To First Lvef Decline Of ≥10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 03)

Figure 3study 4: Cumulative Incidence Of Time To First Lvef Decline Of ≥10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 03)
FDA Label Image

Figure 4duration Of Disease Free Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Kanjinti 04)

Figure 4duration Of Disease Free Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Kanjinti 04)
FDA Label Image

Figure 5duration Of Overall Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Kanjinti 05)

Figure 5duration Of Overall Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Kanjinti 05)
FDA Label Image

Figure 6duration Of Disease Free Survival In Patients With Adjuvant Treatment Of Breast Cancer (study 4) (Kanjinti 06)

Figure 6duration Of Disease Free Survival In Patients With Adjuvant Treatment Of Breast Cancer (study 4) (Kanjinti 06)
FDA Label Image

Figure 7updated Overall Survival In Patients With Metastatic Gastric Cancer (study 7) (Kanjinti 07)

Figure 7updated Overall Survival In Patients With Metastatic Gastric Cancer (study 7) (Kanjinti 07)
This is a survival probability table for a treatment that involves Fluoropyrimidine and Cisplatin. The table shows the number of patients who survived for a certain duration (in months) after treatment. The treatment involves two options: Fluoropyrimidine + Cisplatin and Fluoropyrimidine + Cisplatin + Trastuzumab. The number of patients who survived for each duration is given in the table. The treatment duration ranges from 0 to 50 months. There is some unreadable text in the second row.*
FDA Label Image

Principal Display Panelndc 55513-132-01kanjinti™(trastuzumab Anns)for Injection420 mg/vialfor Intravenous Infusion After Reconstitution420 mg/vialcontents:each Carton Contains One 420 mg Kanjinti Multiple-dose Vial.amgen® Store Vial In The Original Carton To Protect From Light In The Refrigerator At2°c To 8°c (36° F To 46°f) Until Time Of Reconstitution.do Not Shake. Do Not Freeze Reconstituted Solution. (Kanjinti 09)

Principal Display Panelndc 55513-132-01kanjinti™(trastuzumab Anns)for Injection420 mg/vialfor Intravenous Infusion After Reconstitution420 mg/vialcontents:each Carton Contains One 420 mg Kanjinti Multiple-dose Vial.amgen® Store Vial In The Original Carton To Protect From Light In The Refrigerator At2°c To 8°c (36° F To 46°f) Until Time Of Reconstitution.do Not Shake. Do Not Freeze Reconstituted Solution. (Kanjinti 09)
KANJINTI is a medication used for intravenous infusion after reconstruction. It is stored in its original carton to protect it from light in the refrigerator at a temperature of 2°C to 8°C until the time of reconstruction. The text provides details regarding the contents and dosage of KANJINTI.*
FDA Label Image

Kanjinti 0a

Kanjinti 0a

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.